BE863754A - NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS - Google Patents
NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORSInfo
- Publication number
- BE863754A BE863754A BE184992A BE184992A BE863754A BE 863754 A BE863754 A BE 863754A BE 184992 A BE184992 A BE 184992A BE 184992 A BE184992 A BE 184992A BE 863754 A BE863754 A BE 863754A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- vincamine
- brain circulation
- regulators
- new
- Prior art date
Links
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical class C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 title claims description 15
- 210000004556 brain Anatomy 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 claims description 5
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960002726 vincamine Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000003177 cardiotonic effect Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000786363 Rhampholeon spectrum Species 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- ZSUDTJHEHYTFQB-YAFGAGFVSA-N vincamine codecarboxylate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O.C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 ZSUDTJHEHYTFQB-YAFGAGFVSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241001342522 Vampyrum spectrum Species 0.000 description 1
- UVPUQURXWFIUCH-FYXBRNTMSA-N ac1mj4bl Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O.C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 UVPUQURXWFIUCH-FYXBRNTMSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002930 anti-sclerotic effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D461/00—Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Nouveaux dérivés de la vincamine utilisables comme régulateurs de la circulation cérébrale.
<EMI ID=1.1>
Poudre microcristalline blanche de saveur amère, soluble dans l'eau et le méthanol, peu soluble dans les solvants organiques.
<EMI ID=2.1>
<EMI ID=3.1>
1. Spectre U.V. P.M. 701,23
<EMI ID=4.1>
à 263 nm = 305
2. Spectre I.R. (voir figure 1) - Pastille KBr à 3 %.
Le % de transmission se trouve en ordonnée ; la longueur d'onde en ? est donnée en abscisse, échelle supérieure et le nombre d'onde en cm , échelle inférieure.
Procédé de fabrication
On chauffe à reflux, sous atmosphère d'azote pendant 5 heures, 1 mole de vincamine avec 1 mole d'acide adénylique, dans 40 volumes de méthanol. On purifie par passage au noir décolorant la solution obtenue. Puis
on distille sous vide pour réduire la solution au quart de son volume. Après refroidissement, on essore le précipité, on le lave avec du méthanol et on le sèche sous vide à 40[deg.]C.
<EMI ID=5.1>
Vasorégulation cérébrale de la vincamine complétée par l'action cardiotonique de l'acide adénylique. Toxicité :
La DL 100 per os est supérieure à 1 g/kg chez la souris.
<EMI ID=6.1>
Gélules de 20 à 40 mg 2 à 3 fois par jour. II. CODECARBOXYLATE DE VINCAMINE
Poudre microcristalline de couleur jaunâtre,
<EMI ID=7.1>
<EMI ID=8.1>
Identification :
1. Spectre U.V.
<EMI ID=9.1>
2. Spectre I.R. (voir figure 2) - Pastille KBr à 3 % Procédé de fabrication :
On chauffe à reflux pendant une heure sous atmosphère d'azote et bonne agitation, une mole de vincamine et une mole d'acide 5-pyridoxal-phosphorique dans
20 volumes de méthanol à 90 %.
On filtre la solution obtenue, concentre le filtrat sous vide au bain-marie et précipite le sel par <EMI ID=10.1>
Vasorégulation cérébrale de la vincamine complétée par l'action anti-scléreuse de la codêcarboxylase.
Toxicité
La DL 100 per os est supérieure à 1 g/kg chez la souris.
<EMI ID=11.1>
Gélules de 20 à 40 mg 2 à 3 fois par jour.
REVENDICATIONS
1. Dérivé de vincamine constitué par l'adénylate de vincamine.
2. Dérivé de vincamine constitué par le codécarboxylate de vincamine.
3. Utilisation d'un dérivé de vincamine selon l'une quelconque des revendications 1 et 2 comme agent régulateur de la circulation cérébrale.
New vincamine derivatives that can be used as regulators of cerebral circulation.
<EMI ID = 1.1>
White microcrystalline powder with a bitter flavor, soluble in water and methanol, slightly soluble in organic solvents.
<EMI ID = 2.1>
<EMI ID = 3.1>
1. Spectrum U.V. P.M. 701.23
<EMI ID = 4.1>
at 263 nm = 305
2. I.R. spectrum (see figure 1) - 3% KBr pellet.
The% transmission is on the ordinate; the wavelength in? is given on the abscissa, upper scale and the wave number in cm, lower scale.
Manufacturing process
1 mole of vincamine with 1 mole of adenylic acid is heated under reflux under a nitrogen atmosphere for 5 hours in 40 volumes of methanol. The solution obtained is purified by passing to decolorizing black. Then
it is distilled under vacuum to reduce the solution to a quarter of its volume. After cooling, the precipitate is filtered off, washed with methanol and dried under vacuum at 40.degree.
<EMI ID = 5.1>
Cerebral vasoregulation of vincamine supplemented by the cardiotonic action of adenylic acid. Toxicity:
The LD 100 per os is greater than 1 g / kg in mice.
<EMI ID = 6.1>
20 to 40 mg capsules 2 to 3 times a day. II. VINCAMINE CODECARBOXYLATE
Microcrystalline powder of yellowish color,
<EMI ID = 7.1>
<EMI ID = 8.1>
Identification :
1. U.V. spectrum
<EMI ID = 9.1>
2. I.R. spectrum (see figure 2) - 3% KBr pellet Manufacturing process:
One mole of vincamine and one mole of 5-pyridoxal-phosphoric acid are heated under reflux for one hour under a nitrogen atmosphere and good stirring.
20 volumes of 90% methanol.
The solution obtained is filtered, the filtrate is concentrated under vacuum in a water bath and the salt is precipitated by <EMI ID = 10.1>
Cerebral vasoregulation of vincamine supplemented by the anti-sclerotic action of codecarboxylase.
Toxicity
The LD 100 per os is greater than 1 g / kg in mice.
<EMI ID = 11.1>
20 to 40 mg capsules 2 to 3 times a day.
CLAIMS
1. Vincamine derivative consisting of vincamine adenylate.
2. Vincamine derivative consisting of vincamine codecarboxylate.
3. Use of a vincamine derivative according to any one of claims 1 and 2 as a regulating agent of cerebral circulation.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE184992A BE863754A (en) | 1978-02-08 | 1978-02-08 | NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE863754 | 1978-02-08 | ||
BE184992A BE863754A (en) | 1978-02-08 | 1978-02-08 | NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS |
Publications (1)
Publication Number | Publication Date |
---|---|
BE863754A true BE863754A (en) | 1978-05-29 |
Family
ID=25650570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE184992A BE863754A (en) | 1978-02-08 | 1978-02-08 | NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE863754A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0183002A1 (en) * | 1984-10-26 | 1986-06-04 | Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. | Pharmaceutically active salt derivative of 3-hydroxy -5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
US6339085B1 (en) | 1999-03-08 | 2002-01-15 | The University Of Manitoba | Therapeutics for cardiovascular and related diseases |
US6417204B1 (en) | 2000-07-07 | 2002-07-09 | Medicure International Inc. | Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics |
US6489345B1 (en) | 1999-07-13 | 2002-12-03 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
US6586414B2 (en) | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6605612B2 (en) | 2000-02-29 | 2003-08-12 | Medicure International Inc. | Cardioprotective phosohonates and malonates |
US6677356B1 (en) | 1999-08-24 | 2004-01-13 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US6897228B2 (en) | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US7812037B2 (en) | 2004-10-28 | 2010-10-12 | Medicure International, Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
-
1978
- 1978-02-08 BE BE184992A patent/BE863754A/en unknown
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0183002A1 (en) * | 1984-10-26 | 1986-06-04 | Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. | Pharmaceutically active salt derivative of 3-hydroxy -5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
US6890943B2 (en) | 1999-03-08 | 2005-05-10 | Medicure Inc. | Pyridoxal analogues and methods of treatment |
US6339085B1 (en) | 1999-03-08 | 2002-01-15 | The University Of Manitoba | Therapeutics for cardiovascular and related diseases |
US7230009B2 (en) | 1999-03-08 | 2007-06-12 | Medicure, Inc. | Pyridoxal analogues and methods of treatment |
US6489345B1 (en) | 1999-07-13 | 2002-12-03 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US7148233B2 (en) | 1999-08-24 | 2006-12-12 | Merrill Lynch Capital Canada Inc. | Treatment of cardiovascular and related pathologies |
US7144892B2 (en) | 1999-08-24 | 2006-12-05 | Merrill Lynch Capital Canada Inc. | Treatment of cardiovascular and related pathologies |
US7132430B2 (en) | 1999-08-24 | 2006-11-07 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US7125889B2 (en) | 1999-08-24 | 2006-10-24 | Medicure International Inc. | Treating of cardiovascular and related pathologies |
US6677356B1 (en) | 1999-08-24 | 2004-01-13 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US7115626B2 (en) | 1999-08-24 | 2006-10-03 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US7105673B2 (en) | 2000-02-29 | 2006-09-12 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6867215B2 (en) | 2000-02-29 | 2005-03-15 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6780997B2 (en) | 2000-02-29 | 2004-08-24 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6667315B2 (en) | 2000-02-29 | 2003-12-23 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6605612B2 (en) | 2000-02-29 | 2003-08-12 | Medicure International Inc. | Cardioprotective phosohonates and malonates |
US6861439B2 (en) | 2000-03-28 | 2005-03-01 | Medicure International, Inc. | Treatment of cerebrovascular disease |
US6586414B2 (en) | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6897228B2 (en) | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US6417204B1 (en) | 2000-07-07 | 2002-07-09 | Medicure International Inc. | Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics |
US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
US7812037B2 (en) | 2004-10-28 | 2010-10-12 | Medicure International, Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE863754A (en) | NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS | |
CH624952A5 (en) | ||
BE1000573A4 (en) | DERIVATIVES 1- (hydroxystyryl) -5 H 2,3-BENZODIAZEPINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING. | |
SU1122224A3 (en) | Method of obtaining 4-oxy-2-methyl-n-2-pyridyl-2h-1,2-benzthiazine-3-carboxamide-1,1-dioxide | |
FR2464957A1 (en) | PSORALENES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
CH641181A5 (en) | INDOLO-QUINOLIZIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM. | |
CA1310326C (en) | Process for the preparation of 1-hydroxy-5-nitroimidazoles | |
EP0200605A1 (en) | Nitrofuran derivatives, their preparation and their therapeutical use | |
SU1454253A3 (en) | Method of producing 9-(2-oxyethoxymethyl) guanine | |
CH662118A5 (en) | CHLORO-4-FURO- (3,4-C) -PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS BASED ON SUCH DERIVATIVES. | |
EP0021991A1 (en) | Cystamine derivatives, their preparation and pharmaceutical compositions containing them | |
FR2478094A1 (en) | AMMONIO SUBSTITUTED CINNAMYLMORANOLINE DERIVATIVES WITH INHIBITION ACTIVITY OF SUGAR LEVEL IN BLOOD | |
CH645115A5 (en) | PROCESS FOR PREPARING CHLORO-7 METHYL-2 DIHYDRO-3,3A 2H, 9H-ISOXAZOLO (3,2-B) (BENZOXAZINE-1,3) ONE-9. | |
BE884977A (en) | NOVEL N-PHENYL-BENZAMIDES USEFUL IN THE TREATMENT OF MAMMALIAN INFLAMMATION AND PAIN | |
EP0646579A1 (en) | Ketonic indane derivatives and heterocyclic analysis and their use in therapy | |
FR2487347A1 (en) | PROCESS FOR THE PREPARATION OF SUBSTITUTED DIALURIC ACIDS IN POSITION 5 | |
EP0390673A1 (en) | 5-Acyl-benzoxazolinone derivatives, processes for their preparation and pharmaceutical compositions containing them | |
EP0022022A1 (en) | Acylated derivatives of taurine and their salts, and process for their preparation | |
CH622251A5 (en) | ||
EP0646574B1 (en) | Ketonic indane derivatives, their preparation and therapeutic application thereof | |
CH650255A5 (en) | IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
FR2563224A1 (en) | NEW BORNANE DERIVATIVES AND THEIR PREPARATION PROCESS | |
BE633582A (en) | ||
BE537081A (en) | ||
BE862600A (en) | NEW ALKALOID PAMOATES |